SCHEMBL5203739

SCHEMBL5203739

COc1cc2c(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(Cl)c3)ccnc2cc1O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.88
PDGFRA P16234 15/20 0.77
KIT P10721 3/20 0.77
AXL P30530 2/20 0.77
FGFR2 P21802 2/20 0.77
FLT1 P17948 3/20 0.61
FLT4 P35916 3/20 0.61
RIPK2 O43353 2/20 0.61
STK10 O94804 2/20 0.61
ABL1 P00519 2/20 0.61
RET P07949 2/20 0.61
PDGFRB P09619 2/20 0.61
BCR P11274 2/20 0.61
FGFR1 P11362 2/20 0.61
EPHB2 P29323 2/20 0.61
SLC6A3 Q01959 2/20 0.61
DDR1 Q08345 2/20 0.61
MAP4K2 Q12851 2/20 0.61
PTK6 Q13882 2/20 0.61
DDR2 Q16832 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201821 0.94 KDR (0.87) KDRPDGFRAKITAXLFGFR2
SCHEMBL15962876 0.88 KDR (0.69) KDRPDGFRAKITAXLFGFR2
SCHEMBL5202435 0.88 KDR (0.87) KDRPDGFRAKITAXLFGFR2
SCHEMBL7843737 0.87 KDR (0.72) KDRPDGFRAKITAXLFGFR2
SCHEMBL1249562 0.87 KDR (1.00) KDRPDGFRAKITAXLFGFR2
SCHEMBL29366679 0.87 KDR (1.00) KDRPDGFRAKITAXLFGFR2
SCHEMBL29918224 0.87 KDR (1.00) KDRPDGFRAKITAXLFGFR2
SCHEMBL5207899 0.87 KDR (0.86) KDRPDGFRAKITAXLFGFR2
SCHEMBL1876666 0.87 KDR (0.86) KDRPDGFRAKITAXLFGFR2
SCHEMBL5208170 0.86 KDR (0.84) KDRPDGFRAKITAXLFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS KDR 2466/4885PDGFRA 3108/4885KIT 629/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 KDR 3106/4885PDGFRA 3103/4885KIT 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.